methylphenidate

(redirected from Equasym)
Also found in: Thesaurus, Medical.
Related to Equasym: Equasym XL

meth·yl·phen·i·date

 (mĕth′əl-fĕn′ĭ-dāt′, -fē′nĭ-)
n.
A drug, C14H19NO2, chemically related to amphetamine, that acts as a mild stimulant of the central nervous system and is used in its hydrochloride form to treat attention deficit hyperactivity disorder and narcolepsy.

[methyl + phen(yl) + (piper)id(ine) + (acet)ate.]

methylphenidate

(ˌmɛθɪlˈfɛnɪˌdeɪt; ˌmɛθɪlˈfiːnɪˌdeɪt)
n
(Pharmacology) a drug that stimulates the central nervous system and is used, in the form of its hydrochloride, to treat narcolepsy as well as attention deficit disorder

meth•yl•phen•i•date

(ˌmɛθ əlˈfɛn ɪˌdeɪt, -ˈfi nɪ-)

n.
a central nervous system stimulant, C14H19NO2, used in the control of hyperkinetic syndromes and narcolepsy.
[1955–60; methyl + phen- + -ide + -ate2]
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.methylphenidate - central nervous system stimulant (trade name Ritalin) used in the treatment of narcolepsy in adults and attention deficit disorder in childrenmethylphenidate - central nervous system stimulant (trade name Ritalin) used in the treatment of narcolepsy in adults and attention deficit disorder in children
excitant, stimulant drug, stimulant - a drug that temporarily quickens some vital process
Translations

methylphenidate

n metilfenidato
References in periodicals archive ?
The Cricadin sleeping tablets and Equasym medication - used to treat attention deficit hyperactivity disorder - were taken during a break-in.
The haul also included Pethidine tablets, Diamorphine, Concerta XL, Equasym, Medikinet tablets, Ritalin tablets and Palexia tablets.
3 million), less adjustment to contingent consideration payable for EQUASYM ($8.
It was submitted that Anil had made an incorrect entry in the controlled drugs register in relation to equasym tablets, caused or permitted the prescription to be wrongly endorsed, had removed the methadone register on or about June 10, had also left the key in the drugs cabinet and failed to ensure methadone and tamazepam was kept safely.
Adding to this, a recent deal (February 2009) for the European marketing of UCB's Equasym will make Shire a robust player in the ADHD market.
We already have experience of the ADHD market in Europe through our EQUASYM product and we know that there is a patient need for a product with the profile of ELVANSE.
8 million), adjustment to contingent consideration payable for EQUASYM ($8.
UCB key products are Keppra(R) (antiepileptic), Xyzal(R) and Zyrtec(R) (antiallergics), Nootropil(R) (cerebral function regulator), Tussionex(TM) (antitussive) and Metadate(TM) / Equasym XL(TM) (attention-deficit/hyperactivity disorder).
Shire's February 2009 acquisition of non-US rights to Equasym from UCB paves the way for the European launch of Vyvanse 80
Celltech already has considerable physician contact in the neurology field through its Equasym (methylphenidate) range of attention deficit disorder products and other neurological products, and Xyrem will complement this well.
In the six months to June 30, 2011 integration and acquisition costs comprised the integration costs for ABH and Movetis, offset by the release of the contingent consideration liability for EQUASYM.
b) Acquisitions and integration activities: Costs associated with the acquisition of EQUASYM ($0.